Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT05330091 |
Other study ID # |
VCODWP1 |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
February 9, 2022 |
Est. completion date |
October 31, 2022 |
Study information
Verified date |
August 2022 |
Source |
Garden of Life, LLC |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
This decentralized observational study is designed to understand the effects of daily
consumption of once daily woman's probiotic (ODWP) on vaginal pH levels in healthy female
populations ages 19-70 years of age across the United States.
Description:
This decentralized observational study is designed to understand the effects of daily
consumption of once daily woman's probiotic (ODWP) on vaginal pH levels in healthy female
populations ages 19-70 years of age across the United States. Participants will be divided
into two cohorts of 100 participants each; one with a history of vaginal bacteriosis and one
with no history of bacterial vaginosis, with between 20-30 percent of the total participants
being post-menopausal. Participants will be provided and trained to use pH tests on a daily
basis over the course of four menstrual cycles (or equivalent time for amenorrheic
participants). During the first cycle (or equivalent timeframe) of measurement, participants
will not consume neither placebo or once daily woman's probiotics (ODWP); allowing the
establishment of a baseline or wash out period prior to active consumption and measurement of
effect.
Participants will receive ODWP at no charge for consumption over the course of the study.
Participants will be instructed to start and continue consumption over three menstrual cycles
(or equivalent timeframe) based on participant's menstrual status and her demonstrated
ability to self-measure and report vaginal pH via the Validcare Study app based platform (aka
"the app), which is provided as a free, downloadable 21 CFR Part 11 compliant interface for
all patient facing activities and communication with/from the principal investigator for the
study duration.